clopidogrel + esomeprazole

Clopidogrel + esomeprazole is a combination of two pharmaceutical agents commonly co-prescribed in patients at risk for both cardiovascular and gastrointestinal events. Clopidogrel is an antiplatelet prodrug that requires activation by the hepatic enzyme CYP2C19; it irreversibly inhibits the P2Y12 ADP receptor on platelets, thereby reducing platelet aggregation and preventing thrombotic events such as myocardial infarction and stroke. Esomeprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion by inhibiting the H+/K+ ATPase in gastric parietal cells, used to prevent or treat gastrointestinal ulcers and bleeding. However, esomeprazole also inhibits CYP2C19, which can reduce the conversion of clopidogrel to its active metabolite, potentially diminishing its antiplatelet efficacy. Regulatory agencies such as the FDA and EMA recommend avoiding this combination due to reduced effectiveness of clopidogrel when used with esomeprazole[1][2][5]. Some studies suggest that while this combination reduces peptic ulcer recurrence compared to clopidogrel alone, it may not significantly affect platelet aggregation in all patients[4].